CoChat

Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach

Open access
Overgaard, Rune V., Lindberg, Søren Ø., Thielke, Desirée · 2019 · Diabetes, Obesity and Metabolism
Cited by 34

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Aims: Semaglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue approved for the treatment of type 2 diabetes. The impact of switching treatment from another GLP‐1 receptor agonist (GLP‐1RA) to semaglutide was investigated by analyses of exposure‐response models. Methods: HbA1c and body weight time‐course models were developed, using up to 30 weeks of observations from four trials in the semaglutide phase 3 programme. Given the recommended dosing for each GLP‐1RA, pharmacokinetic profiles were simulated based on published population pharmacokinetic models and exposure was adjusted by the relative potencies to ensure that model predictions matched the effects observed in clinical trials. After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended‐release, simulated semaglutide treatment was initiated 1 day after the last once‐daily dose of liraglutide and 1 week after the last once‐weekly doses of dulaglutide or exenatide extended‐release. Results: The potency‐adjusted total effective GLP‐1RA concentration increased after switching from another GLP‐1RA to semaglutide and was associated with reductions ranging from ~0.3% to ~0.8%‐points for HbA1c and from ~2% to ~4% for body weight with semaglutide 1.0 mg. Temporary slight deteriorations in HbA1c were observed after switching to semaglutide 0.25 mg from liraglutide 1.2/1.8 mg or dulaglutide 1.5 mg. Conclusions: Exposure‐response modelling suggests that switching to semaglutide from liraglutide, dulaglutide or exenatide extended‐release results in further reductions in HbA1c and body weight. Initial slight deterioration in outcome values when switching to semaglutide 0.25 mg could be avoided by initiating semaglutide treatment at a higher dose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13479

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

Metadata

Authors
Overgaard, R. V., Lindberg, S. Ø., & Thielke, D.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-08-23
Volume
21
Issue
1
Pages
43-51
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2883897596
Cited by
34
References
17
FWCI
1.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.